Lilah Khoja1, Rachel Palmieri Weber2, Penelope M Webb3, Susan J Jordan4, Aruna Muthukumar5, Jenny Chang-Claude6, Renée T Fortner7, Allan Jensen8, Susanne K Kjaer9, Harvey Risch10, Jennifer Anne Doherty11, Holly R Harris12, Marc T Goodman13, Francesmary Modugno14, Kirsten Moysich15, Andrew Berchuck16, Joellen M Schildkraut17, Daniel Cramer18, Kathryn L Terry19, Hoda Anton-Culver20, Argyrios Ziogas21, Minh Tung Phung22, Gillian E Hanley23, Anna H Wu24, Bhramar Mukherjee25, Karen McLean26, Kathleen Cho27, Malcolm C Pike28, Celeste Leigh Pearce29, Alice W Lee30. 1. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA. Electronic address: lkhoja@umich.edu. 2. Department of Community and Family Medicine, Duke University Medical Center, Durham, NC 27705, USA. Electronic address: rachel.weber@epividian.com. 3. Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia. Electronic address: penny.webb@qimrberghofer.edu.au. 4. School of Public Health, The University of Queensland, Brisbane, Queensland 4006, Australia. Electronic address: s.jordan@uq.edu.au. 5. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA. Electronic address: arumuthu@umich.edu. 6. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: j.chang-claude@dkfz.de. 7. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: r.fortner@dkfz-heidelberg.de. 8. Department of Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, Copenhagen, DK-2100, Denmark. Electronic address: allan@cancer.dk. 9. Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, DK-2100, Denmark; Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, DK-2100, Denmark. Electronic address: susanne@cancer.dk. 10. Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT 06510, USA. Electronic address: harvey.risch@yale.ed. 11. Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, UT 84112, USA. Electronic address: Jen.Doherty@hci.utah.edu. 12. Department of Epidemiology, University of Washington, Seattle, WA 98195, USA; Program in Epidemiology, Department of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. Electronic address: hharris@fredhutch.org. 13. Cancer Prevention and Genetics Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Electronic address: Marc.Goodman@cshs.org. 14. Women's Cancer Research Center, Magee-Women's Research Institute and Hillman Cancer Center, Pittsburgh, PA 15213, USA; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. Electronic address: fm@cs.cmu.edu. 15. Division of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA. Electronic address: Moysich@roswellpark.org. 16. Department of Gynecologic Oncology, Duke University Medical Center, Durham, NC 277170, USA. Electronic address: berch001@mc.duke.edu. 17. Emory University Rollins School of Public Health, Atlanta, GA 30322, USA. Electronic address: joellen.m.schildkraut@emory.edu. 18. Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA 02115, USA; Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. Electronic address: dcramer@bwh.harvard.edu. 19. Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA 02115, USA; Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. Electronic address: kterry@bwh.harvard.edu. 20. Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA 92617, USA. Electronic address: hantoncu@hs.uci.edu. 21. Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA 92617, USA. Electronic address: aziogas@uci.edu. 22. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA. Electronic address: phungmt@umich.edu. 23. Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: gillian.hanley@vch.ca. 24. Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA. Electronic address: anna.wu@med.usc.edu. 25. Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: bhramar@umich.edu. 26. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA. Electronic address: karenmcl@umich.edu. 27. Department of Pathology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA. Electronic address: kathcho@med.umich.edu. 28. Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: pikem@mskcc.org. 29. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA. Electronic address: lpearce@umich.edu. 30. Department of Public Health, California State University, Fullerton, CA 92831, USA. Electronic address: alicelee@fullerton.edu.
Abstract
OBJECTIVE: To evaluate the association between hysterectomy and ovarian cancer, and to understand how hormone therapy (HT) use and endometriosis affect this association. METHODS: We conducted a pooled analysis of self-reported data from 11 case-control studies in the Ovarian Cancer Association Consortium (OCAC). Women with (n = 5350) and without ovarian cancer (n = 7544) who never used HT or exclusively used either estrogen-only therapy (ET) or estrogen+progestin therapy (EPT) were included. Risk of invasive epithelial ovarian cancer adjusted for duration of ET and EPT use and stratified on history of endometriosis was determined using odds ratios (ORs) with 95% confidence intervals (CIs). RESULTS: Overall and among women without endometriosis, there was a positive association between ovarian cancer risk and hysterectomy (OR = 1.19, 95% CI 1.09-1.31 and OR = 1.20, 95% CI 1.09-1.32, respectively), but no association upon adjusting for duration of ET and EPT use (OR = 1.04, 95% CI 0.94-1.16 and OR = 1.06, 95% CI 0.95-1.18, respectively). Among women with a history of endometriosis, there was a slight inverse association between hysterectomy and ovarian cancer risk (OR = 0.93, 95% CI 0.69-1.26), but this association became stronger and statistically significant after adjusting for duration of ET and EPT use (OR = 0.69, 95% CI 0.48-0.99). CONCLUSIONS: The hysterectomy-ovarian cancer association is complex and cannot be understood without considering duration of ET and EPT use and history of endometriosis. Failure to take these exposures into account in prior studies casts doubt on their conclusions. Overall, hysterectomy is not risk-reducing for ovarian cancer, however the inverse association among women with endometriosis warrants further investigation.
OBJECTIVE: To evaluate the association between hysterectomy and ovarian cancer, and to understand how hormone therapy (HT) use and endometriosis affect this association. METHODS: We conducted a pooled analysis of self-reported data from 11 case-control studies in the Ovarian Cancer Association Consortium (OCAC). Women with (n = 5350) and without ovarian cancer (n = 7544) who never used HT or exclusively used either estrogen-only therapy (ET) or estrogen+progestin therapy (EPT) were included. Risk of invasive epithelial ovarian cancer adjusted for duration of ET and EPT use and stratified on history of endometriosis was determined using odds ratios (ORs) with 95% confidence intervals (CIs). RESULTS: Overall and among women without endometriosis, there was a positive association between ovarian cancer risk and hysterectomy (OR = 1.19, 95% CI 1.09-1.31 and OR = 1.20, 95% CI 1.09-1.32, respectively), but no association upon adjusting for duration of ET and EPT use (OR = 1.04, 95% CI 0.94-1.16 and OR = 1.06, 95% CI 0.95-1.18, respectively). Among women with a history of endometriosis, there was a slight inverse association between hysterectomy and ovarian cancer risk (OR = 0.93, 95% CI 0.69-1.26), but this association became stronger and statistically significant after adjusting for duration of ET and EPT use (OR = 0.69, 95% CI 0.48-0.99). CONCLUSIONS: The hysterectomy-ovarian cancer association is complex and cannot be understood without considering duration of ET and EPT use and history of endometriosis. Failure to take these exposures into account in prior studies casts doubt on their conclusions. Overall, hysterectomy is not risk-reducing for ovarian cancer, however the inverse association among women with endometriosis warrants further investigation.
Authors: Susan J Jordan; Christina M Nagle; Michael D Coory; Diane Maresco; Melinda M Protani; Neha A Pandeya; Kanchana D Balasubramaniam; Penelope M Webb Journal: Eur J Cancer Date: 2013-07-25 Impact factor: 9.162
Authors: Rikki A Cannioto; Britton Trabert; Elizabeth M Poole; Joellen M Schildkraut Journal: Cancer Causes Control Date: 2017-03-10 Impact factor: 2.506
Authors: Ko-Hui Tung; Lynne R Wilkens; Anna H Wu; Katharine McDuffie; Jean H Hankin; Abraham M Y Nomura; Laurence N Kolonel; Marc T Goodman Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-03 Impact factor: 4.254
Authors: Weiva Sieh; Shannon Salvador; Valerie McGuire; Rachel Palmieri Weber; Kathryn L Terry; Mary Anne Rossing; Harvey Risch; Anna H Wu; Penelope M Webb; Kirsten Moysich; Jennifer A Doherty; Anna Felberg; Dianne Miller; Susan J Jordan; Marc T Goodman; Galina Lurie; Jenny Chang-Claude; Anja Rudolph; Susanne Krüger Kjær; Allan Jensen; Estrid Høgdall; Elisa V Bandera; Sara H Olson; Melony G King; Lorna Rodriguez-Rodriguez; Lambertus A Kiemeney; Tamara Marees; Leon F Massuger; Anne M van Altena; Roberta B Ness; Daniel W Cramer; Malcolm C Pike; Celeste Leigh Pearce; Andrew Berchuck; Joellen M Schildkraut; Alice S Whittemore Journal: Int J Epidemiol Date: 2013-04 Impact factor: 7.196
Authors: Susan J Jordan; Adèle C Green; David C Whiteman; Suzanne P Moore; Christopher J Bain; Dorota M Gertig; Penelope M Webb Journal: Int J Cancer Date: 2008-04-01 Impact factor: 7.396
Authors: Nicolas Wentzensen; Elizabeth M Poole; Britton Trabert; Emily White; Alan A Arslan; Alpa V Patel; V Wendy Setiawan; Kala Visvanathan; Elisabete Weiderpass; Hans-Olov Adami; Amanda Black; Leslie Bernstein; Louise A Brinton; Julie Buring; Lesley M Butler; Saioa Chamosa; Tess V Clendenen; Laure Dossus; Renee Fortner; Susan M Gapstur; Mia M Gaudet; Inger T Gram; Patricia Hartge; Judith Hoffman-Bolton; Annika Idahl; Michael Jones; Rudolf Kaaks; Victoria Kirsh; Woon-Puay Koh; James V Lacey; I-Min Lee; Eva Lundin; Melissa A Merritt; N Charlotte Onland-Moret; Ulrike Peters; Jenny N Poynter; Sabina Rinaldi; Kim Robien; Thomas Rohan; Dale P Sandler; Catherine Schairer; Leo J Schouten; Louise K Sjöholm; Sabina Sieri; Anthony Swerdlow; Anna Tjonneland; Ruth Travis; Antonia Trichopoulou; Piet A van den Brandt; Lynne Wilkens; Alicja Wolk; Hannah P Yang; Anne Zeleniuch-Jacquotte; Shelley S Tworoger Journal: J Clin Oncol Date: 2016-06-20 Impact factor: 44.544